Company
Faeth Therapeutics
Faeth Therapeutics is pioneering multi-node inhibition of the PAM (PI3K/AKT/mTOR) pathway — the most frequently altered oncogenic pathway in cancer.
Also known as Faeth, Faeth Therapeutics, Inc.
- Status
- Acquiredas of 2026-09-18Source (opens in a new tab)
- Business model
- B2B
- Founded
- 2019
- Legal name
- Faeth Therapeutics, Inc.
- faeththerapeutics.com (opens in a new tab)
- LinkedIn (opens in a new tab)
- Press page (opens in a new tab)
- Careers (opens in a new tab)
Claim, correct or request removal
Record updated 28 September 2026
About
We exist to improve the lives of patients by developing novel therapeutics to treat some of the most devastating types of cancer.
Funding snapshot
- Total raised
- $24.4MSEC form D sum, as of 2026-09-28Source (opens in a new tab)
- Latest round
- Round, $24.4M2025-08-01
Funding rounds
- Round, 2025
- $24.4M2025-08-01, SEC form D sold, 35 investors
About the company
- Status notes
- In February 2026, Faeth was acquired by Sensei Biotherapeutics in a transaction that included a concurrent $200 million private placement.
Products
- Web
- IEM
- Web
- NEAAR
- Other
- PIKTOR
- Web
- PIKTOR
Exit
- Acquisition
- 2026-02
Loading relationship preview